Please ensure Javascript is enabled for purposes of website accessibility

2 Reasons Alexion Pharmaceuticals' Stock Could Rise

By Brian Feroldi - Feb 19, 2016 at 1:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the rare-disease-focused biotech are down substantially from their recent highs. Here are two reasons to believe shares will rebound in 2016.

Image source: TBIT via pixabay.

Alexion Pharmaceuticals' (ALXN) stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as measured by the iShares Nasdaq Biotechnology ETF -- and they have surrendered nearly 25% of their value since January 1st. 

ALXN Chart

Great companies always find a way to bounce back when their shares get slammed without a good reason, and I believe Alexion has what it takes to rebound. Below are two reasons Alexion's stock could rise from here.

New drugs could surprise
Alexion recently became more than just a one-drug company after it put two new rare disease drugs -- Strensiq and Kanuma -- up for sale. Neither of these drugs have had time to impact the company's final statements much -- Strensiq sales were only $12 million in the most recent quarter, and Kanuma didn't contribute at all -- but there is reason to believe that could change quickly.

Management is forecasting that combined sales of these drugs will be between $150 million and $175 million for the full year, but that could be conservative guidance depending on how quickly the drugs ramp up sales. Analysts see peak sales potential for each of these drugs topping $1 billion. If Alexion's management team is purposely under-promising on sales so it can later over-deliver, then I could easily see its shares reacting positively. 

Clinical updates could give shares a boost
Biotech stocks tend to rise or fall drastically as companies provide investors with clinical updates from their pipelines, and Alexion should have at least four data readouts in 2016 that investors can look forward to.

The first two relate to its blockbuster drug Soliris, which is currently being tested in late-stage trials for four additional clinical indications. The company plans on releasing clinical updates on two of its studies during the year. First is Alexion's PROTECT study of Soliris in Delayed Graft Function, a serious complication that can occur in organ transplantation. A second study it will be sharing data on is REGAIN, which looks at Soliris' use in refractory Myasthenia Gravis, a neurological disorder. Data from both are expected by the middle of the year.

Beyond Soliris, investors should get clinical updates on two newer drugs in earlier-stage clinical trails that hold potential to be growth drivers in a few years' time. Alexion will be reporting data from its Phase 1/2 data of SBC-103, which is a potential enzyme replacement therapy being studied as a treatment for mucopolysaccharidosis IIIB, this coming March. The company will also give investors a look at data related to ALXN1007, a compound being studied in the rare Gastrointestinal Graft-versus-Host Disease. 

While it's unlikely all of the company's clinical updates from these trials will be positive, but just a few successes could be enough to reignite the company's share price.

Tying it all together
Alexion's management team has forecasted that its non-GAAP earnings per share for 2016 will land between $5.00 and $5.20, which includes a $0.31 hit due to expected currency translation. If the company can successfully deliver on its profit forecast -- and Alexion has a strong history of meeting or exceeding its guidance -- then its shares are currently trading hands for roughly 29 times the low end of its full-year guidance range. While value investors might be hard-pressed to call a multiple like that cheap, I think Alexion is a premium company that deserves a premium price tag. That's especially true when you consider that analysts believe Alexion will grow its bottom line by more than 20% annualized over the next five years.

Biotech stocks are out of favor right now, which makes right now a great time to go bargain hunting for the strongest names in the bunch. With several catalysts on the horizon and a reasonable share price, I think growth-focused biotech investors should considering giving Alexion's shares a closer look.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.